Cannabinoid-Based Drugs Seek New High, Part II
Developers Anticipate Additional Approvals after FDA Nod for Epidiolex
CAR T Cells Show Solid Progress
Tumors are Being Deprived of Cover by New CAR T-Cell Technologies
Top 10 Biopharma IPOs of January—June 2018
Number of Companies Going Public, and the Amount They Raise, Show Growth
Single-Cell Cloning Remains a Challenge
Evolving Technologies Help Make It Easier to Meet Regulatory Requirements
For full access to this article login to GEN Select now.
Supplement: Cancer Immunotherapies Development Barriers
Current State of Protocol Design Impacting Small to Mid-Sized Biotech Companies
- Over the past century, a greater understanding of how our immune system recognizes and targets foreign invaders for destruction has emerged, resulting in cancer immunotherapy breakthroughs. Today, more than 900 immunotherapy agents are in clinical development, and more than 1,000 in preclinical development, according to the Cancer Research Institute. ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.